| Literature DB >> 30639242 |
Joanna R Kovalski1, Aparna Bhaduri2, Ashley M Zehnder3, Poornima H Neela3, Yonglu Che1, Glenn G Wozniak3, Paul A Khavari4.
Abstract
Proximity-dependent biotin labeling (BioID) may identify new targets for cancers driven by difficult-to-drug oncogenes such as Ras. Therefore, BioID was used with wild-type (WT) and oncogenic mutant (MT) H-, K-, and N-Ras, identifying known interactors, including Raf and PI3K, as well as a common set of 130 novel proteins proximal to all Ras isoforms. A CRISPR screen of these proteins for Ras dependence identified mTOR, which was also found proximal to MT Ras in human tumors. Oncogenic Ras directly bound two mTOR complex 2 (mTORC2) components, mTOR and MAPKAP1, to promote mTORC2 kinase activity at the plasma membrane. mTORC2 enabled the Ras pro-proliferative cell cycle transcriptional program, and perturbing the Ras-mTORC2 interaction impaired Ras-dependent neoplasia in vivo. Combining proximity-dependent proteomics with CRISPR screening identified a new set of functional Ras-associated proteins, defined mTORC2 as a new direct Ras effector, and offers a strategy for finding new proteins that cooperate with dominant oncogenes.Entities:
Keywords: BioID; CRISPR; MAPKAP1; Ras; cancer; mTOR; proteomics
Mesh:
Substances:
Year: 2019 PMID: 30639242 PMCID: PMC6386588 DOI: 10.1016/j.molcel.2018.12.001
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970